In this article, we will discuss KYNMOBI ™ (Overview). So, let’s get started.
KYNMOBI (apomorphine hydrochloride) is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease.
Dosage and Administration
• Sublingual administration only
• Dose initiation should be supervised by a healthcare provider
• Treatment with a concomitant antiemetic, e.g. trimethobenzamide, is
recommended, beginning 3 days prior to initial dose of KYNMOBI™.
• The dose range for KYNMOBI is 10 mg to 30 mg per dose, administered sublingually, as needed.
• KYNMOBI™ doses should be separated by at least 2 hours
• Maximum of 5 doses per day; maximum single dose is 30 mg.
Dosage Forms and Strength
KYNMOBI™ sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg of apomorphine hydrochloride.
• Concomitant use of KYNMOBI™ with 5HT3 antagonists
• Hypersensitivity to apomorphine or any of its ingredients including sodium metabisulfite.
Warnings and Precautions
• Nausea and vomiting may occur
• Falling asleep during activities of daily living and daytime somnolence may occur, discontinue KYNMOBI if occurs
• Syncope and hypotension/orthostatic hypotension may occur, monitor
• Oral mucosal irritation may occur, which may require pausing or discontinuing treatment
• Falls may occur, or increase
• May cause hallucinations and psychotic-like behavior
• May cause impulse control and impulsive behaviors, consider dose reduction or discontinuing KYNMOBI if occurs.
• Withdrawal-emergent hyperpyrexia and confusion may occur with rapid dose reduction or withdrawal
• May prolong QTc and cause torsades de pointes or sudden death; consider risk factors prior to initiation.
Most common adverse reactions incidence at least 10% in patients treated with KYNMOBI™ and with an incidence greater than placebo) were nausea, oral/pharyngeal soft tissue swelling, oral/pharyngeal soft tissue pain and paraesthesia, dizziness, and somnolence.